Charles River Laboratories acquired Vigene Biosciences, a gene therapy CDMO, for $292.5M plus $57.5M milestones.
Danaher bought Precision NanoSystems, an mRNA-based vaccine developer for gene therapy applications.
Sanofi acquired Translate Bio, mRNA therapeutics firm, for $3.2B.
Thermo Fisher acquiring PPD CRO for $17.4B potentially supporting gene therapy trials.
Roche purchased GenMark Diagnostics for $1.8B, enhancing molecular diagnostics relevant to therapies.
Digital health and biotech M&A surged in 2021 Q2 with $34.7B across ~1,600 deals, including gene therapy targets.
No specific recent news found on 'Second life for a gene therapy', Takeda Phase 2/3 success, or UK cancer biotech $83M raise in provided 2021-2022 search results.